Sentences with phrase «overall survival at»

Estimated overall survival at five years was 14.5 % higher for patients who received chemotherapy and radiation compared to patients who received radiation alone (86.1 % versus 71.6 %).

The effect was a 28 % reduction in the risk of death, which is statistically and clinically significant, and an 11 % absolute gain in overall survival at five years.»

Not exact matches

A clinical trial conducted by researchers at the Virginia G. Piper Cancer Center Clinical Trials, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen), showed that a new drug called MM - 398, given in combination with 5 - flourouracil (5FU) and leucovorin, produced a significant overall survival rate in patients with advanced, previously - treated pancreatic cancer.

The researchers found that at five years, very few patients who received chemotherapy experienced disease relapses, showing high rates of distant metastases - free survival, disease - free survival and overall survival, which confirms that they derived benefit from chemotherapy.

A follow - up of the 48 patients who were evaluable at a median time of 24 months indicated no statistical differences between the two groups in terms of overall or progression - free survival.

Immunotherapy doubles overall survival and improves quality of life, with fewer side effects, in a treatment - resistant and rapidly progressing form of head and neck carcinoma, reports a large, randomized international trial co-led by investigators at the University of Pittsburgh Cancer Institute (UPCI).

The other way is to look at overall survival.

In a paper published online by the New England Journal of Medicine, investigators at Dana - Farber and research centers around the world found that the drug combination — given as a single pill known as TAS - 102 — not only extended patients» overall survival, but also delayed the advance of the disease and did so with very few side effects.

These statistically significant and clinically meaningful improvements in overall response and survival rates resulted from a phase Ib / II clinical study performed at the HonorHealth Research Institute, a partnership of HonorHealth and TGen.

In absolute terms, the overall survival rate at five years was 11 % higher in the ipilimumab arm (65 %) than in the placebo arm (54 %).

Ipilimumab as adjuvant therapy significantly improves overall survival in patients with high risk stage III melanoma, according to the EORTC 18071 phase III trial results presented for the first time at the ESMO 2016 Congress in Copenhagen.

Now, at 5.3 years median follow up, the impact on overall survival is reported and represents a 28 % reduction of the relative risk of death (hazard ratio 0.72, p = 0.001).

In the first study to report on the association of aspirin use with breast cancer outcomes in a large patient population, researchers examined the pattern of aspirin use, cancer pathology and overall survival in 1,000 patients treated at the Abramson Cancer Center of the University of Pennsylvania and diagnosed with breast cancers, including receptor positive, HER2 - positive and triple negative cancers.

At this point, 72 percent of enzalutamide patients and 63 percent of placebo patients were alive at the trial cutoff date showing a 29 percent overall improvement in survivaAt this point, 72 percent of enzalutamide patients and 63 percent of placebo patients were alive at the trial cutoff date showing a 29 percent overall improvement in survivaat the trial cutoff date showing a 29 percent overall improvement in survival.

The study, based on work done by Doris Germain of Mt. Sinai Hospital, found that the combination of the drugs bortezomib and fulvestrant — versus fulvestrant alone — doubled the rate of survival at 12 months and reduced the chance of cancer progression overall.

In other words, if depth of response hints at overall survival, then maybe depth of response could be an early sign that an investigational drug is working.

The Swedish study involving 25,474 women is the first to quantify the combined effects of smoking and age at menopause on overall mortality in terms of survival time by investigating the role of smoking as a possible effect modifier.

They compared gene expression from tumors of 740 patients (combined from two studies) to overall patient survival to arrive at these correlations.

But a model that incorporated both rates showed that the mosquitoes» overall probability of survival is higher at higher temperatures.

Although CRC affects all racial and ethnic groups, African Americans carry an excessive burden of disease with the highest overall incidence, highest incidence of advanced stage at presentation, highest mortality, and lowest survival rates compared to any other ethnic or racial group.

To look at farming's impact on overall survival rates, marine biologists Jennifer Ford and the late Ransom Myers of Dalhousie University in Halifax, Nova Scotia, examined three decades» worth of data from Ireland, Scotland, and Canada.

In a study presented today at a meeting of women's cancer specialists, overall survival for women who received standard chemotherapy treatment plus bevacizumab was a median five months longer than for women who received the standard chemotherapy treatment alone.

In the last two decades lung cancer therapy has improved, but the overall 5 - year survival rate is still quite low at 17 %.

A new study, presented today at The International Liver Congress ™ 2016 in Barcelona Spain, demonstrates that the use of antiviral therapy for patients in the immune tolerant phase of Hepatitis B (HBV) prolongs overall survival and reduces the risk of the most common form of liver cancer (Hepatocellular Carcinoma, HCC) and scarring of the liver (cirrhosis).

The drug lenvatinib can significantly improve overall survival rates in a group of thyroid cancer patients whose disease is resistant to standard radioiodine treatment, according to new research from the Perelman School of Medicine at the University of Pennsylvania.

The study babies who were born at 26 weeks had an overall survival rate of 81.4 percent and a survival without severe impairment rate of 75.6 percent.

A study by researchers at Brigham and Women's Hospital (BWH) found that brachytherapy treatment was associated with better cause - specific survival and overall survival in women with cervical cancer.

Treating patients with high - dose radiotherapy after chemotherapy and surgery for malignant pleural mesothelioma does not achieve improvements in local relapse and overall survival, according to data from a prospective randomized phase II trial presented at ESMO 2014 Congress in Madrid.

At five - years post-treatment, patients in the HFX arm had the highest overall survival rates at 37.1 percent (HR 0.81, 95 percent CI), compared to 33.7 percent for the AFX - C arm, 29.3 percent for the SFX arm, 29.0 percent for the AFX - S arAt five - years post-treatment, patients in the HFX arm had the highest overall survival rates at 37.1 percent (HR 0.81, 95 percent CI), compared to 33.7 percent for the AFX - C arm, 29.3 percent for the SFX arm, 29.0 percent for the AFX - S arat 37.1 percent (HR 0.81, 95 percent CI), compared to 33.7 percent for the AFX - C arm, 29.3 percent for the SFX arm, 29.0 percent for the AFX - S arm.

«We didn't see an improvement in overall survival or a statistically significant increase in progression - free survival, as defined in the context of this trial,» says the study's senior author, Minesh P. Mehta, M.B., Ch.B., Professor of Radiation Oncology at the University of Maryland School of Medicine and a radiation oncologist at the University of Maryland Marlene and Stewart Greenebaum Cancer Center.

At five years, 34 of the 102 patients had achieved a complete response (disappearance of their cancer for a period of time), with an estimated 64 percent of patients surviving with or without disease (median five - year overall survival was 40.5 months) and an estimated 52 percent surviving without disease progression.

At five years, the rates for disease - free and overall survival were 26 percent and 40 percent, respectively, with a median overall survival of four years.

«Overall survival for patients with HIV infection after transplant is comparable to that seen in people who were not HIV - infected,» said lead author Joseph Alvarnas, MD, associate clinical professor in the department of hematology and director of value - based analytics at the City of Hope National Medical Center in Duarte, CA.

The study, led by Deborah Armstrong at the Johns Hopkins Kimmel Cancer Center in Baltimore, Maryland, builds upon evidence from eight other clinical trials showing an overall survival benefit of approximately one year for women treated with IP chemotherapy after «optimal debulking» — surgery to remove most, if not all, of the cancer in the abdomen.

In the Eastern Cooperative Oncology Group Trial, interferon alfa - 2b was shown to improve disease - free and overall survival, but in many other trials it has not been shown to be effective at prolonging overall survival.

«What we see is an association between shorter periods of progression - free survival and overall survival in patients whose blood has higher levels of hypermethylated DNA, and we can see this very early on, after just four weeks of treatment,» says Sara Sukumar, Ph.D., professor of oncology at the Johns Hopkins University School of Medicine and member of the Kimmel Cancer Center, who developed the test with Johns Hopkins scientist Mary Jo Fackler, Ph.D., and others.

To figure out how well the test reflected disease trends, results of the blood tests were analyzed to look at two measures of survival: progression - free and overall survival over the study period.

Removal of a fifth course of chemotherapy containing cytarabine resulted in worse overall survival and disease - free survival in pediatric patients with low - risk acute myeloid leukemia (AML), according to the results (abstract 10515) of a pooled analysis of two Children's Oncology Group (COG) trials presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2 — 6 in Chicago.

However, among patients who had uninformative cytogenetic or molecular features but who were MRD < 0.1 % at the end of induction I, the disease - free survival (HR, 1.86; 95 % CI, 1.18 — 2.92; P =.008) and overall survival (HR, 1.91; 95 % CI, 1.01 — 3.61; P =.046) were almost twice as high in patients who received five treatment courses compared with four courses.

Overall survival showed a trend toward improvement with sunitinib, but did not reach significance, at 8.95 months vs. 6.89 months (HR = 1.17; 90 % CI, 0.77 — 1.78; P = 0.27).

The positive study was the S ‐ TRAC trial, in which sunitinib demonstrated improved disease - free survival (DFS) but not overall survival (OS) in patients at high risk of recurrence of RCC following nephrectomy.

The overall objective of her work is to understand how survival drives related metabolism organize decisions made at higher levels.

Other indicators of adiposity, such as body fat, also have been examined for mortality associations.26, 27 However, the independent association between body fat and mortality in the older population has not been adequately demonstrated.14, 27 Researchers speculate that the controversial association between adiposity and mortality in older individuals may be attributable to selective survival, cohort effects, or unadjusted confounding.41 We found that BMI or waist circumference, but not percent body fat, predicted overall mortality in adults at least 60 years old.

To assess in a preliminary fashion the potential benefit of AdhCMV - TK and Ad - hCMV - Flt3L treatment of primary malignant gliomas by assessing overall survival (OS) at 12 and 24 months.

Landmark overall survival rates at two and three years (OS24, OS36) were 34.8 % and 26.1 % respectively.

The investigators looked at the prognostic association of individual alterations within both treatment arms and found that IDH and ATRX «showed significant association» with progression - free survival and overall survival in multivariate analysis.

Treatments invented at St. Jude have helped push the overall childhood cancer survival rate from 20 % to more than 80 % since it opened more than 50 years ago.

Median overall survival, commonly referred to as median OS, is the time point at which 50 % of patients in a trial are expected to have survived.

A phase III trial published last year showed that dabrafenib combined with trametinib in patients with metastatic disease was superior to dabrafenib alone, in terms of progression - free survival (22 % vs 12 % at 3 years; hazard ratio [HR], 0.71) and overall survival (44 % vs 32 % at 3 years; HR, 0.75).

At a median follow - up of 65 months, both variables independently, negatively predicted disease progression, progression - free survival (PFS) and overall survival (OS).